English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

MabThera (rituximab) – Conditions or restrictions regarding supply and use - L01XC02

Updated on site: 08-Oct-2017

Medication nameMabThera
ATC CodeL01XC02
Substancerituximab
ManufacturerRoche Registration Ltd

A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Names and addresses of the manufacturers of the biological active substance

Genentech Inc.

1000 New Horizons Way

Vacaville, CA 95688

USA

Genentech, Inc.

1 Antibody Way

Oceanside, CA 92056 5802

USA

Samsung BioLogics

300, Songdo Bio Way (Daero) Yeonsu-gu, Incheon 21987, Korea

Name and address of the manufacturer responsible for batch release

Roche Pharma AG

Emil-Barell-Str. 1

D-79639 Grenzach-Wyhlen

Germany

B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) ) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines webportal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Risk Management Plan (RMP)

The MAH shall perform the pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed and subsequent updates of the RMP.

An updated RMP should be submitted:

At the request of the European Medicines Agency.

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

Additional risk minimisation measures

Rheumatoidis arthritis:

The MAH must ensure that all physicians who are expected to prescribe MabThera are provided with the following:

Product information

Physician information

Patient information

Patient Alert card

The Physician information about MabThera should contain the following key elements:

The need for close supervision during administration in an environment where full resuscitation facilities are immediately available

The need to check, prior to MabThera treatment, for infections, for immunosuppression, for prior/current medication affecting the immune system and recent history of, or planned, vaccination

The need to monitor patients for infections, especially PML, during and after MabThera treatment

Detailed information on the risk of PML, the need for timely diagnosis of PML and appropriate measures to diagnose PML

The need to advise patients on the risk of infections and PML, including the symptoms to be aware of and the need to contact their doctor immediately if they experience any.

The need to provide patients with the Patient Alert Card with each infusion

The Patient information about MabThera should contain the following key elements:

Detailed information on the risk of infections and PML

Information on the signs and symptoms of infections, especially PML, and the need to contact their doctor immediately if they experience any

The importance of sharing this information with their partner or caregiver

Information on the Patient Alert Card

The Patient Alert Card for MabThera in non-oncology indications should contain the following key elements:

The need to carry the card at all times and to show the card to all treating health care professionals

Warning on the risk of infections and PML, including the symptoms

The need for patients to contact their health care professional if symptoms occur

The Physician information, Patient information and Patient Alert Card must be agreed with the National Competent Authorities prior to distribution.

Subcutaneous formulation:

All healthcare professionals administering MabThera subcutaneous formulation will be provided with an Educational Material (« step by step guide » and « comparison card ») to minimise the risk of off label use and administration route error.

Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

Description

Due date

Submission of clinical study reports from the clinical trials BO22334 and BO25341 including reports on long-term safety in relation to BSA (as a measure for exposure variation) and to gender as follows:

 

 

Final CSR BO22334a (both stages)

Q3/2018

 

 

 

 

Final CSR BO25341a (both parts)

Q4/2018

a To report analysis of primary endpoint (Ctrough non-inferiority) for Part 2 and available safety and immunogenicity data from both parts of the ongoing study.

Immunogenicity data from BO22334/SABRINA and

 

B025341/SAWYER will be reviewed on an ongoing manner.

 

An Immunogenicity report from both stages of BO22334/SABRINA

by end of Q4/2016

and from B025341/SAWYER to be submitted by Q4 2016 and as

(immunogenicity report)

planneda by Q3/2018 and Q4/2018 respectively.

by Q3 and Q4/2018 (see

 

 

above)

 

 

Comments

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed